E&G Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $763K | Buy |
3,509
+45
| +1% | +$9.98K | 0.17% | 102 |
|
|
2025
Q4 | $791K | Hold |
3,464
| – | – | 0.18% | 97 |
|
|
2025
Q3 | $802K | Buy |
3,464
+5
| +0.1% | +$1.02K | 0.19% | 101 |
|
|
2025
Q2 | $642K | Hold |
3,459
| – | – | 0.17% | 116 |
|
|
2025
Q1 | $725K | Hold |
3,459
| – | – | 0.2% | 100 |
|
|
2024
Q4 | $615K | Hold |
3,459
| – | – | 0.17% | 110 |
|
|
2024
Q3 | $683K | Hold |
3,459
| – | – | 0.19% | 106 |
|
|
2024
Q2 | $593K | Hold |
3,459
| – | – | 0.17% | 110 |
|
|
2024
Q1 | $630K | Buy |
3,459
+103
| +3% | +$17.8K | 0.2% | 101 |
|
|
2023
Q4 | $520K | Hold |
3,356
| – | – | 0.18% | 106 |
|
|
2023
Q3 | $500K | Sell |
3,356
-50
| -1% | -$7.34K | 0.18% | 111 |
|
|
2023
Q2 | $459K | Buy |
3,406
+100
| +3% | +$14.7K | 0.16% | 119 |
|
|
2023
Q1 | $527K | Sell |
3,306
-220
| -6% | -$33.6K | 0.2% | 113 |
|
|
2022
Q4 | $570K | Hold |
3,526
| – | – | 0.21% | 107 |
|
|
2022
Q3 | $473K | Sell |
3,526
-100
| -3% | -$14.3K | 0.17% | 116 |
|
|
2022
Q2 | $555K | Hold |
3,626
| – | – | 0.19% | 109 |
|
|
2022
Q1 | $588K | Sell |
3,626
-100
| -3% | -$14.5K | 0.16% | 117 |
|
|
2021
Q4 | $505K | Sell |
3,726
-200
| -5% | -$23.6K | 0.13% | 132 |
|
|
2021
Q3 | $423K | Buy |
+3,926
| New | +$449K | 0.11% | 142 |
|
|
2021
Q2 | – | Sell |
-3,726
| Closed | -$420K | – | 142 |
|
|
2021
Q1 | $403K | Sell |
3,726
-37
| -1% | -$3.96K | 0.12% | 140 |
|
|
2020
Q4 | $403K | Buy |
3,763
+50
| +1% | +$4.8K | 0.12% | 135 |
|
|
2020
Q3 | $325K | Sell |
3,713
-546
| -13% | -$51.4K | 0.11% | 136 |
|
|
2020
Q2 | $418K | Buy |
4,259
+259
| +6% | +$22.8K | 0.16% | 109 |
|
|
2020
Q1 | $305K | Hold |
4,000
| – | – | 0.15% | 121 |
|
|
2019
Q4 | $354K | Hold |
4,000
| – | – | 0.13% | 150 |
|
|
2019
Q3 | $303K | Hold |
4,000
| – | – | 0.12% | 153 |
|
|
2019
Q2 | $291K | Buy |
4,000
+255
| +7% | +$20K | 0.12% | 154 |
|
|
2019
Q1 | $302K | Sell |
3,745
-1,455
| -28% | -$119K | 0.13% | 151 |
|
|
2018
Q4 | $479K | Hold |
5,200
| – | – | 0.22% | 121 |
|
|
2018
Q3 | $492K | Buy |
+5,200
| New | +$493K | 0.19% | 132 |
|
|
2017
Q4 | – | Sell |
-3,900
| Closed | -$347K | – | 200 |
|
|
2017
Q3 | $347K | Sell |
3,900
-1,800
| -32% | -$137K | 0.16% | 122 |
|
|
2017
Q2 | $413K | Sell |
5,700
-5,200
| -48% | -$350K | 0.2% | 104 |
|
|
2017
Q1 | $710K | Buy |
10,900
+2,200
| +25% | +$138K | 0.36% | 65 |
|
|
2016
Q4 | $545K | Sell |
8,700
-2,000
| -19% | -$122K | 0.32% | 71 |
|
|
2016
Q3 | $675K | Sell |
10,700
-300
| -3% | -$19.4K | 0.4% | 61 |
|
|
2016
Q2 | $681K | Buy |
+11,000
| New | +$670K | 0.41% | 60 |
|
Other funds holding ABBV
VCM
VPM
E&G Advisors's ABBV Position: Q1 2026 in Review
E&G Advisors increased its AbbVie (ABBV) stake by 1.3% in Q1 2026, buying an estimated $9.98K and bringing the position to 3,509 shares worth $763K. The position accounts for 0.17% of the portfolio, ranked #102.
E&G Advisors first reported a position in ABBV in Q2 2016 and has held it in 36 quarters since. The position peaked at $802K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- E&G Advisors held 3,509 shares of AbbVie worth $763K as of Q1 2026.
- E&G Advisors bought 45 AbbVie shares in Q1 2026, an estimated $9.98K.
- AbbVie made up 0.17% of E&G Advisors's portfolio in Q1 2026, its #102 holding.
- E&G Advisors first reported a position in AbbVie in Q2 2016 and has held it in 36 quarters since.
- E&G Advisors's AbbVie position peaked at $802K in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on E&G Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.